Atea Pharmaceuticals Inc (AVIR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Atea Pharmaceuticals Inc (AVIR) has a cash flow conversion efficiency ratio of -0.102x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.22 Million) by net assets ($275.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check AVIR strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Atea Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Atea Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See AVIR book value for net asset value and shareholders' equity analysis.
Atea Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atea Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Meteoric Resources NL
F:RNF
|
-0.820x |
|
Hellenic Exchanges - Athens Stock Exchange SA
AT:EXAE
|
0.162x |
|
Saratoga Investment Corp
NYSE:SAR
|
0.018x |
|
Rejlers AB (publ)
ST:REJL-B
|
0.029x |
|
Comp SA
WAR:CMP
|
0.041x |
|
Select Harvests Ltd
AU:SHV
|
0.005x |
|
Changchun Yidong Clutch Co Ltd
SHG:600148
|
0.014x |
|
Huitong Construction Group Co.Ltd.
SHG:603176
|
N/A |
Annual Cash Flow Conversion Efficiency for Atea Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Atea Pharmaceuticals Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Atea Pharmaceuticals Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $275.43 Million | $-132.03 Million | -0.479x | -55.26% |
| 2024-12-31 | $438.87 Million | $-135.50 Million | -0.309x | -100.73% |
| 2023-12-31 | $555.19 Million | $-85.39 Million | -0.154x | +18.56% |
| 2022-12-31 | $640.57 Million | $-120.98 Million | -0.189x | -54.14% |
| 2021-12-31 | $710.08 Million | $-87.00 Million | -0.123x | -122.62% |
| 2020-12-31 | $547.80 Million | $296.73 Million | 0.542x | +109.55% |
| 2019-12-31 | $-49.57 Million | $-12.81 Million | 0.258x | +18.20% |
| 2018-12-31 | $-36.16 Million | $-7.91 Million | 0.219x | -- |
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company … Read more